Incyte Co. (NASDAQ:INCY) EVP Yao Wenqing Sells 3,165 Shares

Incyte Co. (NASDAQ:INCY) EVP Yao Wenqing sold 3,165 shares of Incyte stock in a transaction on Friday, November 29th. The stock was sold at an average price of $95.00, for a total value of $300,675.00. Following the transaction, the executive vice president now directly owns 98,473 shares of the company’s stock, valued at approximately $9,354,935. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Yao Wenqing also recently made the following trade(s):

  • On Monday, December 2nd, Yao Wenqing sold 16,835 shares of Incyte stock. The stock was sold at an average price of $95.00, for a total transaction of $1,599,325.00.
  • On Friday, November 1st, Yao Wenqing sold 7,960 shares of Incyte stock. The shares were sold at an average price of $85.00, for a total transaction of $676,600.00.
  • On Tuesday, October 29th, Yao Wenqing sold 2,040 shares of Incyte stock. The shares were sold at an average price of $85.00, for a total transaction of $173,400.00.

INCY stock opened at $94.10 on Wednesday. The stock has a market capitalization of $20.28 billion, a P/E ratio of 114.76, a PEG ratio of 1.37 and a beta of 1.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.01 and a current ratio of 5.02. Incyte Co. has a one year low of $57.00 and a one year high of $95.36. The company has a 50 day moving average price of $85.04 and a two-hundred day moving average price of $81.63.

Incyte (NASDAQ:INCY) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.27. Incyte had a return on equity of 20.07% and a net margin of 19.21%. The company had revenue of $551.58 million for the quarter, compared to analyst estimates of $534.73 million. During the same quarter in the prior year, the company posted $0.41 EPS. The business’s revenue for the quarter was up 22.7% compared to the same quarter last year. Research analysts forecast that Incyte Co. will post 2.14 earnings per share for the current fiscal year.

A number of equities analysts have issued reports on INCY shares. JMP Securities lifted their target price on shares of Incyte from $107.00 to $110.00 and gave the stock a “market outperform” rating in a research report on Monday, September 30th. ValuEngine lowered shares of Incyte from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 5th. BMO Capital Markets began coverage on shares of Incyte in a research note on Thursday, September 12th. They set a “market perform” rating and a $85.00 price objective for the company. Mizuho reissued a “buy” rating and set a $98.00 price objective on shares of Incyte in a research note on Wednesday, November 27th. Finally, BidaskClub upgraded Incyte from a “hold” rating to a “buy” rating in a research report on Thursday, November 28th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $93.05.

Large investors have recently made changes to their positions in the company. Commonwealth Bank of Australia lifted its position in Incyte by 49.2% during the second quarter. Commonwealth Bank of Australia now owns 376 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 124 shares during the period. Pathstone Family Office LLC purchased a new stake in Incyte in the 2nd quarter valued at about $34,000. Captrust Financial Advisors purchased a new stake in Incyte in the 2nd quarter valued at about $35,000. Benjamin F. Edwards & Company Inc. increased its stake in shares of Incyte by 617.7% during the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 445 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 383 shares during the last quarter. Finally, First Manhattan Co. acquired a new position in shares of Incyte during the 2nd quarter valued at about $50,000. 91.10% of the stock is owned by institutional investors and hedge funds.

About Incyte

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Featured Story: What is a Candlestick Chart?

Insider Buying and Selling by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit